Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]

April 5, 2026 updated by: Yonsei University

[Background] Hyperinflation caused by increased airflow limitation and emphysema change commonly accompanies dyspnea, which leads to inactivity, reducing exercise capacity, and deconditioning. Hyperinflation in COPD is also associated with decreased left and right end-diastolic volume and stroke volume, and cardiac output.

Previous studies investigated effects of ICS/LABA or LABA/LAMA versus placebo on cardiac function in patients with COPD and lung hyperinflation. However, there are not evidences for effects of LABA/LAMA on cardio-pulmonary exercise capacity.

Cardiopulmonary exercise testing (CPET) is an exercise stress test with concomitant expired gas analysis, which provides objective parameters of functional capacity. Since CPET can assess integrated exercise responses of cardiopulmonary, vascular, and skeletomuscular systems, it can reveal abnormalities that are not apparent in a resting state. Moreover, change in oxygen consumption during exercise and anaerobic threshold can be evaluated.

The investigators would like to investigate change in cardio-pulmonary exercise capacity via CPET before and after tiotropium/olodaterol inhalation in COPD patients with hyperinflation, which is the first clinical study. Association between change in cardio-pulmonary exercise capacity with function of heart and lung would be further evaluated with cardiac magnetic resonance (CMR) and lung function.

The in investigators expect to enhance cardio-pulmonary exercise capacity though the improvement in cardiac and pulmonary function with tiotropium/olodaterol inhalation. This result would provide evidence to encourage to treat with dual bronchodilators in COPD patients with hyperinflation.

[Study objectives] To investigate and compare the bronchodilator effect of tiotropium/olodaterol on cardio-pulmonary exercise capacity in hyperinflated COPD patients

[Study design] Prospective, single-center, one-arm clinical study After using the tiotropium/olodaterol inhaler for 4weeks, the investigators will compare pre- and post- cardio-pulmonary exercise capacity, cardiac function, lung function, symptoms and quality of life

[Statistic methods] For continuous variables, data will be presented as median, minimum, maximum with standard deviation (95% confidence intervals). For categorical variables, data will be presented as percentage (95% confidence intervals). Paired t-test for continuous variables and chi-squared test for categorical variables will be performed to compare the difference in results before and after inhalation of the tiotropium/olodaterol inhaler.

This is a pilot study; therefore, sample size cannot be calculated by power analysis, because of the absence of any data in the literature that could be reviewed. A sample size is expected to be 40 patients. When the drop-out rate 10% is considered, final sample size is expected to be 44.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • South Korea
      • Seoul, South Korea
        • Severance Hospital, Yonsei University Health System

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

36 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. The person who voluntarily signed the consent form
  2. Adults over 40 years of age
  3. Patients who diagnosed with COPD
  4. Patients with smoking history of 10 packs or more
  5. Patients who are taking or in need of tiotropium/olodaterol inhaler for the treatment of COPD
  6. Patients in a clinically stable state within 3 months of screening
  7. Patients who confirmed FEV1/FVC < 0.7 and FEV1 <80% after using bronchodilator
  8. Patients who confirmed FRC > 125%
  9. Patients who confirmed mMRC > 2

Exclusion Criteria:

  1. Patients with a history of asthma
  2. Patients with asthma- COPD overlap
  3. Patients with serious disease other than COPD
  4. Patients with unstable or life-threatening cardiac arrhythmias
  5. Patients hospitalized for heart failure or myocardial infarction within 1 year of screening
  6. Patients with systolic ejection fraction less than 40%
  7. Patients with unstable ischemic heart disease
  8. Patients receiving regular oxygen therapy for 1hour or more per day
  9. Others who are difficult to participate in the research under judgment of the investigation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: tiotropium/olodaterol
Drug: tiotropium/olodaterol
From Visit 2(Baseline), test subjects will be use tiotropium/olodaterol inhaler once a day for 4 weeks. After that, visit the hospital at 4 weeks to receive examination and terminate participation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of maximum oxygen consumption
Time Frame: At 4 weeks
After 4 weeks of tiotropium/olodaterol inhaler use, measure the change in the maximum oxygen consumption (VO2, ml/kg/min) during the cardio-pulmonary exercise test compared to the baseline
At 4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in cardiopulmonary exercise test results after 4 weeks compared to baseline
Time Frame: At 4 weeks
After 4 weeks of tiotropium/olodaterol inhaler use, measure the secondary outcomes during the cardio-pulmonary exercise test compared to the baseline
At 4 weeks
Change in cardiac MRI results after 4 weeks compared to baseline
Time Frame: At 4 weeks
After 4 weeks of tiotropium/olodaterol inhaler use, measure the secondary outcomes during the cardiac MR compared to the baseline
At 4 weeks
Change in echocardiography results after 4 weeks compared to baseline
Time Frame: At 4 weeks
After 4 weeks of tiotropium/olodaterol inhaler use, measure the secondary outcomes during the echocardiography compared to the baseline
At 4 weeks
Change in spirometry results after 4 weeks compared to baseline
Time Frame: At 4 weeks
After 4 weeks of tiotropium/olodaterol inhaler use, measure the secondary outcomes during pulmonary function test compared to the baseline
At 4 weeks
Change in questionnaire evaluation and quality of life (CAT score) after 4 weeks compared to baseline
Time Frame: At 4 weeks

< Questionnaire >

COPD Assessment Test(CAT) score : from 0 to 40, the higher scores denote a more severe impact of COPD on patient's life
At 4 weeks
Change in questionnaire evaluation and quality of life (mMRC score) after 4 weeks compared to baseline
Time Frame: At 4 weeks

< Questionnaire >

Modified Medical Research Council(mMRC) scale : from 0 to 4, the higher scale, the more deterioration in severity of dyspnea
At 4 weeks
Change in questionnaire evaluation and quality of life (BDI score) after 4 weeks compared to baseline
Time Frame: At 4 weeks

< Questionnaire >

Baseline Dyspnea Index(BDI score : from 0 to 12, the lower the score, the more deterioration in severity of dyspnea
At 4 weeks
Change in questionnaire evaluation and quality of life (TDI score) after 4 weeks compared to baseline
Time Frame: At 4 weeks

< Questionnaire >

Transitional Dyspnea Index(TDI) score : from -9 to +9, the lower the score, the more deterioration in severity of dyspnea
At 4 weeks
Change in serologic cardiac biomarkers after 4 weeks compared to baseline
Time Frame: At 4 weeks

< Serologic cardiac biomarker>

NTproBNP, high sensitive troponin, soluble ST2
At 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yonsei University

Investigators

  • Principal Investigator: Ji Ye Jung, Severance Hospital, Yonsei University Health System

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 23, 2021

Primary Completion (Actual)

July 25, 2024

Study Completion (Actual)

July 25, 2024

Study Registration Dates

First Submitted

July 12, 2021

First Submitted That Met QC Criteria

August 2, 2021

First Posted (Actual)

August 6, 2021

Study Record Updates

Last Update Posted (Actual)

April 7, 2026

Last Update Submitted That Met QC Criteria

April 5, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 4-2021-0635

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Disease

Clinical Trials on tiotropium/olodaterol

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe